Kodiak Sciences Inc.

NASDAQ:KOD

Biotechnology

Healthcare
$97.81 -0.08%

-$0.03 today

Market cap
$6.40B
Beta
2.21
P/E (TTM)
-9.6
EPS (TTM)
-$3.73
52W Low $3.43High $47.84

Volume 0.74M

Average 1.10M

KOD EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Kodiak Sciences Inc.NASDAQ: KOD

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$66.22M, compared with -$54.92M a year earlier. Trailing-twelve-month EBITDA was -$225.15M.

Context

  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -36.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$66.22M-9.3% QoQ
Last fiscal yearDec 2025
-$203.65M-36.2% YoY
LTMSep 2026
-$225.15M-18.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.6%+100.0%+120.6 pp
1 year-36.2%+100.0%+136.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(203.65M) USD
Year-over-year change
-36.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How KOD compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -18.0% is the 5th highest of 10, against a peer median of -19.1%.
KOD Competitors
EBITDA for KOD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$5.75B USD+6.1%+3.4%37.0%
BLCOBausch + Lomb CorporationLTM Jun 2026$742M USD+61.3%-3.6%13.9%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.08M USD-482.8%—18634.1%
OCGNOcugen, Inc.LTM Mar 2026-$64.18M USD-19.1%—1437.5%
OCSOculis Holding AGLTM Mar 2026-CHF 94.13M CHF+7.5%—18676.3%
BLTEBelite Bio, IncLTM Sep 2026-$129.44M USD-116.5%——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M USD+3.9%—185.2%
KODKodiak Sciences Inc.LTM Sep 2026-$225.15M USD-18.0%——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$260.06M USD-79.4%—3415.1%
OCULOcular Therapeutix, Inc.LTM Mar 2026-$274.24M USD-55.5%—527.0%
Peer median (excluding KOD) —-19.1%-0.1%982.2%

Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue8.71M11M25.95M26.71M0
Gross Profit(8.71M)(11M)(25.95M)(26.71M)0
Gross Margin—————
Research & Development217.34M267.59M206.3M126.1M182.37M
Selling, General & Admin41M62.79M71.02M34.05M52.02M
Operating Expenses258.34M330.38M251.37M160.14M234.39M
Depreciation & Amortization8.71M11M25.95M26.71M26.32M
EBITDA(258.26M)(322.8M)(234.53M)(149.5M)(203.65M)
EBITDA Margin—————
Operating Income(267.05M)(341.38M)(277.32M)(186.85M)(234.39M)
Operating Margin—————
Interest Income298K7.07M16.73M11.15M4.52M
Interest Expense22K18K13K00
Other Income / Expenses61K7.56M16.83M10.64M4.42M
Income Before Tax(266.99M)(333.82M)(260.49M)(176.21M)(229.97M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(266.99M)(333.82M)(260.49M)(176.21M)(229.97M)
Net Margin—————
EPS (Basic)(5.16)(6.39)(4.97)(3.35)(4.32)
EPS (Diluted)(5.16)(6.39)(4.97)(3.35)(4.32)
Weighted Avg Shares51.79M52.25M52.41M52.58M53.21M
Weighted Avg Shares (Diluted)51.79M52.25M52.41M52.58M53.21M

Kodiak Sciences Inc.

NASDAQ:KOD

Intrinsic Alpha fair value

Locked

Current Price

$97.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.